Verve Therapeutics | 8-K: Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
Verve Therapeutics | DEFA14A: Others
Verve Therapeutics | DEF 14A: Definitive information statements
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Verve Therapeutics | 8-K: Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
Verve Therapeutics | DEFA14A: Others
Verve Therapeutics | DEF 14A: Definitive proxy statements
Verve Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Verve Therapeutics | 8-K: Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Verve Therapeutics | 8-K: Current report
Verve Therapeutics | 8-K: Current report
No Data